Cancer vaccines

Show results for

Unknown (6615)
Genomics (234)
Transcriptomics (182)
Proteomics (87)
Clinical (47)
Other (6)
Metabolomics (6)
Models (4)
Genomic (3)
Methylation profiling (1)

Organisms

Mus musculus (124)
Homo sapiens (119)
Gallus gallus (24)
Ovis aries (18)
Dermestes lardarius (17)
Senegalia senegal (17)
Frangula alnus (17)
Pandalus borealis (17)
Pachymenia carnosa (17)
Bothrops moojeni (17)
Quercus alba (17)
Megathura crenulata (17)
Gossypium hirsutum (17)
Bos taurus (17)
Rhodotorula (16)
Medicago sativa (10)
Chlorocebus sabaeus (2)
Macaca fascicularis (2)
Macaca mulatta (2)
Leptospira interrogans serovar Copenhageni str. Fiocruz L1-130 (1)
Salmonella enterica subsp. enterica serovar Paratyphi A (1)
Dirofilaria immitis (1)
Mesocricetus auratus (1)
Plasmodium falciparum (1)
Ceratonia siliqua (1)
Oncorhynchus nerka (1)
Trypanosoma cruzi (1)
Fusobacterium nucleatum (1)
Human immunodeficiency virus 1 (1)
Oryctolagus cuniculus (1)

Organisms

Homo sapiens (87)
Mus musculus (82)
Macaca mulatta (4)
Mycolicibacterium phlei DSM 43239 = CCUG 21000 (2)
Gallus gallus (2)
Mycolicibacterium phlei DSM 43071 (1)
Mycolicibacterium phlei DSM 43072 (1)
Mycolicibacterium phlei DSM 43070 (1)
Fusobacterium nucleatum (1)
Macaca (1)
mouse gut metagenome (1)
Rattus norvegicus (1)

Repository

ENA (218)
geo (136)
biostudies-arrayexpress (94)
pride (40)
EGA (9)
MassIVE (8)
MetaboLights (6)
iProX (4)
dbGaP (3)
BioModels (2)
Cell Collective (2)
jPOST (1)

Tissue

Blood (8)
Cell culture (7)
Bone marrow (5)
Mononuclear cell (5)
Dendritic cell (4)
Peripheral blood mononuclear cell (4)
Brain (3)
Macrophage (3)
B cell (2)
Blood plasma (2)
Colon (2)
Primary cell line cell (2)
Blood serum (1)
Breast (1)
Breast cancer cell (1)
Dermal fibroblast (1)
Epithelial cell (1)
Fibroblast (1)
Glioma cell (1)
HeLa cell (1)
Neoplastic cell (1)
Ovary (1)
Permanent cell line cell (1)
Pluripotent stem cell (1)
Primary cell (1)
Prostate gland (1)
Somatic cell (1)
T cell (1)

Disease

Colorectal Neoplasms (15)
Acute myeloid leukemia (5)
Breast Neoplasms (4)
Carcinoma (4)
Brain cancer (3)
Chronic lymphocytic leukemia (3)
BCG Vaccine (2)
Lymphoma (2)
Melanoma (2)
Pancreatic Neoplasms (2)
Adenocarcinoma (2)
Lung Neoplasms (2)
Neoplasms (2)
Breast cancer (2)
Glioblastoma (2)
2) lymphoid malignancies (1)
Prostate and colon cancer (1)
Incurable lung, esophageal, colorectal, gastric, gallbladder, or breast cancer (1)
Unresectable colorectal cancer (1)
Prostatic Neoplasms (1)
Neoplasm Metastasis (1)
Stomach Neoplasms (1)
Colonic Neoplasms (1)
Colorectal cancer (1)
Adenoma (1)
Brain glioblastoma multiforme (1)
Colon adenocarcinoma (1)
Colon cancer (1)
Fibrosarcoma (1)
Ovarian carcinoma (1)

Technology Type

Mass Spectrometry (40)
Shotgun proteomics (20)
Bottom-up proteomics (7)
Data-dependent acquisition (7)
Immunopeptidomics (5)
Mass spectrometry assay (4)
Affinity purification coupled with mass spectrometry proteomics (4)
Mass spectrometry (2)
Gel-based experiment (2)
SWATH MS (2)

Instrument Platform

NextSeq 500 (6)
Orbitrap Fusion Lumos (6)
Illumina NovaSeq 6000 (5)
Liquid Chromatography MS - negative - reverse phase (3)
Illumina HiSeq 2000 (2)
Liquid Chromatography MS - positive - reverse phase (2)
NextSeq 1000 (1)
Illumina HiSeq X (1)
Illumina HiSeq 2500 (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
Q Exactive HF (1)
Q Exactive Plus (1)
QExactive Plus (1)
TimsTOF Pro 2 (1)
Liquid Chromatography MS - alternating - HILIC (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)

Publication Date

2025 (41)
2024 (34)
2013 (31)
2026 (23)
2022 (21)
2015 (21)
2023 (18)
2014 (16)
2021 (15)
2020 (11)
2019 (10)
2016 (10)
2010 (10)
2009 (7)
2011 (6)
2012 (5)
2018 (4)
2017 (3)
2008 (3)
2005 (2)

UNIPROT ID/AC

Q3UNK5 (1)
P70293 (1)
C4NUM1 (1)

CHEBI ID

CHEBI:167922 (1)
CHEBI:32664 (1)
CHEBI:17536 (1)
CHEBI:15676 (1)
CHEBI:16708 (1)
CHEBI:16335 (1)
CHEBI:16449 (1)
CHEBI:16761 (1)

Metabolite Name

Aminovaleric acid betaine (1)
VaL-Gly (1)
Tiglyl carnitine C5:1 (1)
Taurodeoxycholic acid isomer (1)
Stearoylcarnitine isomer (1)
Sn-glycero-3-phospho-1-Inositol (1)
Ser Thr Glu isomer (1)
Sedoheptoluse-7-phosphate (1)
Saringosterol isomer (1)
Ribothymidine isomer (1)
Ribose-5-phosphate (1)
PS(22:1/20:4) (1)
PS(20:5/20:0) (1)
PS(20:1/18:2) (1)
Propionyl carnitine C3 (1)
PI(20:4/18:0) (1)
PG(22:6/17:1) (1)
PG(22:6/16:1) (1)
PG(22:2/16:1) (1)
PG(20:4/18:2) (1)
PG(20:4/18:1) (1)
PG(20:4/18:0) (1)
PG(20:4/16:1) (1)
PG(18:2/22:6) (1)
PG(18:1/22:6) (1)
PG(18:1/22:5) (1)
PG(16:1/20:5) (1)
PG(16:1/16:0) (1)
PG (22:6/18:3) (1)
PE(P-18:1/20:4) (1)

First Public Date

2025 (38)
2024 (38)
2026 (26)
2014 (26)
2023 (21)
2022 (11)
2020 (10)
2017 (10)
2015 (10)
2019 (8)
2021 (6)
2018 (5)
2016 (5)
2013 (4)

Modelling Approach

Ordinary differential equation model (2)

Study status

Completed (29)
Terminated (6)
Active, not recruiting (3)
Withdrawn (3)
Not yet recruiting (2)
Not provided (2)
Recruiting (2)

Lab affiliation

Institute for Research in Immunology and Cancer, Department of Biochemistry, Department of Chemistry, Université de Montréal, Québec, Canada H3T 1J4 (6)
Center of experimental therapeutics Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Centre de recherche Agora Rue du Bugnon 25A CH-1005 Lausanne (2)
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea (2)
Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany (2)
1. Monash Proteomics and Metabolomics Facility, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia 2. School of Clinical Sciences, Department of Medicine, Monash University, Clayton, Victoria, Australia (1)
All liquid chromatography MS/MS (LC-MS/MS) data were searched against the relevant database using PEAKS 10.5 or Peaks X Pro (Bioinformatics Solution Inc.). For peptide identification, tolerance was set at 10 ppm and 0.01 Da for precursor and fragment ions, respectively. The occurrences of oxidation (M), deamidation and TMT modification were set as variable modifications (1)
BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC UMR 7178, University of Strasbourg, CNRS (1)
BriaCell Therapeutics Corporation, Berkeley, CA, USA (1)
Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium (1)
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany (1)
Dep. of Oncology-Pathology, Karolinska Institutet, Scilifelab, Stockholm, Sweden (1)
Department of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, Louisiana 70112 (1)
Department of Biological Engineering, Massachusetts Institute of Technology (1)
Department of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia (1)
Department of Molecular Biology, Princeton University (1)
Department of Peptide-based Immunotherapy (1)
Department of Veterinary Biosciences, The University of Melbourne (1)
Departments of Pathology, Microbiology & Immunology, and Biology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (1)
Dept. of Computer Science, University of Tübingen Germany, Center for Bioinformatics, University of Tübingen, Germany, Quantitative Biology Center, University of Tübingen, Germany, Max Planck Institute for Developmental Biology, Germany, (1)
Fudan Uninversity, Shanghai Cancer Center (1)
German Cancer Reseach Center (DKFZ) (1)
Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain (1)
Institute for Research in Immunology and Cancer, Department of Chemistry, Université de Montréal, Montréal, Québec, Canada H3T 1J4 (1)
Laboratoire de Spectrométrie de Masse Bio-Organique (LSMBO), Institut Pluridisciplinaire Hubert Curien (IPHC), UMR 7178, Université de Strasbourg, CNRS, Strasbourg, France (1)
Laboratory of Physical and Chemical Methods for Structure Analysis, V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia (1)
Massachusetts Institute of Technology (1)
Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine (1)
OmicScouts GmbH Lise-Meitner-Str. 30 D-85354 Freising Germany (1)
The Affiliated Hospital of Jiaxing University (1)
University of Oxford (1)

Keyword

Vaccines (16)
Stage IV colon cancer (13)
Recurrent colon cancer (12)
Stage IV rectal cancer (10)
Sargramostim (9)
Recurrent rectal cancer (9)
Stage IV pancreatic cancer (8)
Recurrent pancreatic cancer (7)
Adenocarcinoma of the colon (7)
Stage III colon cancer (6)
Adenocarcinoma of the rectum (6)
Stage II pancreatic cancer (5)
Stage III pancreatic cancer (5)
Stage IV non-small cell lung cancer (5)
Stage IV breast cancer (5)
Recurrent breast cancer (5)
Recurrent non-small cell lung cancer (5)
Extensive stage small cell lung cancer (4)
Recurrent small cell lung cancer (4)
Leucovorin (4)
Stage III rectal cancer (4)
Monatide (IMS 3015) (3)
Vaccine (3)
Aldesleukin (3)
Metronidazole (3)
Adenocarcinoma of the pancreas (3)
Male breast cancer (3)
Stage II colon cancer (3)
Liver metastases (3)
Antibodies (3)

IsPrivate

False (2)

Submitter Keywords

Immuno-oncology (2)

Classification

bacteria (1)

Study type

Transcription profiling by array (50)
Interventional (46)
Proteomic profiling by array (18)
RNA-seq of coding RNA (10)
RNA-seq of coding RNA from single cells (6)
Human - One-color microarray (2)
Unknown experiment type (1)
One-color microarray (1)
Animal - High-throughput sequencing (1)
ATAC-seq (1)
Ribo-seq (1)
DNA-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)
Observational (1)

Release Date

2022 (1005)
2023 (862)
2021 (823)
2025 (640)
2024 (583)
2020 (529)
2019 (322)
2018 (287)
2016 (267)
2017 (254)
2015 (247)
2014 (217)
2013 (141)
2011 (102)
2012 (101)
2010 (78)
2026 (74)
2009 (64)
2008 (41)
2006 (18)
2007 (15)
2005 (11)
2003 (8)
2004 (6)
2001 (4)
1998 (4)
1999 (3)
2002 (2)
2000 (1)

Location

United States (37)
Japan (3)
Cuba (2)
United Kingdom (2)
Puerto Rico (1)
Israel (1)
Canada (1)
Netherlands (1)

Previous page
1 / 719
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 719
Next page

Sort by:

Relevance

Page size

Metabolites interact with microorganisms and vaccines

we engineered a β-glucan (Dex)-stabilized mulberry leaf lipid-based nanovaccine (DPML@OVA-CpG) that protected vaccine components during GI transit and facilitated their specific delivery to the GALTs. Following oral administration, the DPML@OVA-CpG underwent M cell-mediated transcytosis in the small...

2026-08-25 | MTBLS15453 | MetaboLights

Iimmunopeptidomics pipeline for generation of personalized oncolytic cancer vaccines.

We used a streamlined pipeline for the generation of personalized cancer vaccines starting from the isolation and selection of the most immunogenic peptide candidates expressed on the tumour cells and ending in the generation of efficient therapeutic oncolytic cancer vaccines. We used MHC-I immunoaf...

ORGANISM(S): Mus musculus (Mouse)

2022-04-06 | PXD026463 | Pride

Personalized Breast Cancer Vaccines Based on Genome Sequencing

PRJNA801392 | ENA

Personalized Breast Cancer Vaccines Based on Genome Sequencing

PRJNA801393 | ENA

Proteomic analysis for In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses

ORGANISM(S): Mus Musculus

2022-07-14 | PXD035315 |

Personal Neoantigen Cancer Vaccines

PRJNA401959 | ENA

Pharmacological Targeting of ALDH1a2 in Dendritic Cells Enhances Antigen Presentation, T Cell Activation and Anti-tumor immunity

Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...

2025-11-03 | MTBLS10389 | MetaboLights

The Promise of Preventive Cancer Vaccines.

Not available

S-EPMC4494347 | biostudies-literature

Development of Therapeutic Vaccines for Ovarian Cancer.

Not available

S-EPMC7711901 | biostudies-literature

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream.

Not available

S-EPMC8233841 | biostudies-literature

Previous page
1 / 719
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 719
Next page

Sort by:

Relevance

Page size

7185 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets